merck is up 2%. >> bristol-myers, a lot of -- everybody loves brifl ss bristol-myers. it trades close to 30 times forward earnings. when you get headlines like this on a friday before this conference, that's what's going to happen. so if you want to play the valuation game i'd rather own eli lilly at 22 times forward earnings. but better yet, i'd own pfizer which is in the teens. pfizer, slow steady wins the race. bristol-myers, you'll get a shot to buy it cheper than it is right now. if you're looking for the middle trade, it's eli lilly. >> i think the reason this isn't necessarily something you should read is they're 40% oncology revenues and this is to me a much bigger hit for these guys. i don't know this reads to all the other players. guy says this is a stock you don't need to chase here. i will say it's traded down after hours to a level where you can begin to pick up the stock and i think that's something people will probably begin to do because i think people, as guy said, are overreacting on a friday afternoon to news that -- you know. >> we've said time and

drugs known as immunotherapy, development by merck, astrazenecao and roach and others. >> the therapy treatments we're developing today attempt to unblock, if you will or activate the body's immune system to begin to fight off the cancer again. >> bristol myers and merck have two of the newest on the market for the skin cancer melanoma and lung cancer as well. analysts are anticipating on how these drugs and others work for different cancers as well as how they fair in combination with other medicines. >> while merck and bristol myers are the leaders of the two approved drugs, roche and astraza has two drugs not far behind. and the debate is a. how differentiates a these drugs, and is there any difference and are they all essentially showing the same data. >> and analysts are watching on updates for drugs for breast cancer including one from pfizer called i brands, an experimental drug from puma technology. puma stock sank when data was release add head of the conference and analysts say the company will seek to change investor minds about the drug at asco. and they are watching a rac

you heard him tell us that the drug was from merck.w it was okay. >> and it's not, it's not the merck that you're thinking. it's counterfeit. >> reporter: investigators are now checking out the garage behind the grocery store. you can see children on the street watching all this unfold, but right over my shoulder, is the supermarket here in this central los angeles neighborhood and they are convinced that back here in one of the garages she has essentially a supply of this medicine that she is selling on the streets. >> go ahead, open it. [ speaking foreign language ] >> reporter: so i ask, why sell in the streets? [ speaking foreign language ] >> reporter: she has no answer. then there's the heat. well into the 90s, on the day we were there. she thinks it's okay in the heat. [ speaking foreign language ] >> yeah, she says it's hot. >> reporter: what temperature should this be stored at? >> it's got to be somewhere between 60 and 75 degrees. if there is antibiotic inside, you may not be getting anything in there because it's all been d

to the people of baltimore, and the demonstrators across merck merck -- america, i heard your call foro justice, no peace. your peace is sincerely needed as i work to deliver justice on behalf of this young man. to those that are angry, hurt or have their own experiences of injust disat the hands of police officers, i urge you to channel the anger peacefully. i have heard your call for no justice, no peace, however, your peace is sincerely needed as i work to deliver justice on behalf of freddy gray. to the rank and file officers of the baltimore city police officer, please know the accusations of these six officers are not an indictment on the entire force. my father was an officer, my mother was an officer, my recently departed and beloved grandfather was one of the founding members of the first black police organizations in massachusetts. i can them you that the actions of these officers will not, and should not in anyway damage the important working relationships between police and ros cute -- prosecutors as we continue to reduce crime in baltimore. thank you for your courage, comm

the san jose merck re news reports they want the camera policy changed. he said it allows officers to turn the camera off by discretion. >>> statue of jesus stolen from an east bay church. it was connected to a large crucifix outside the catholic church of transfiggation in castro valley. sergio has more. >> reporter: this is what the cross looks like now. you can see that the bronze sculpture of christ is missing. parishioners figure it was stolen tuesday night. when you get right up to the cross you seek the bolts that used to hold the bronze figure in place have been broken. leaders public it was pried off or 'pulled off. many members of the church are shocked some someone would steal a sacred figure from their church. >> has been reported, and the people are looking, and all this scrap metal merchants and people who buy this kind of thing have been warned and something offered a reward and so -- and the police are investigating. and so we are waiting for something to turn up. >> reporter: members of the community have also offered to help pay for a re

we're watching bigger companies like bristol-myers, merck, astrazeneca and merck.ot a ton of movement, bristol is up half a percent. this is going to continue to evolve as we lead up to the conference at the end of this month. right now, puma unfortunately the big loser in the after hours. >> you know, puma had been talked about as a takeout target. what happens to the stock -- to the company i should say with the stock down 18%? >> yeah, it's tough. citi was coming out ahead of the drop saying on positive data it can go up 10 to 20%. it's going in the opposite direction. positive data could have boosted the outlook for a potential takeover. so you have to wonder if they're running a process, what potential acquirers could be thinking about the data and whether it's strong enough to yield a big takeover premium or takeover at all. analysts haven't weighed in. we should see what they think about this. >> meg, thanks so much. karen, you're into biotech. >> this is the kind of thing we're afraid of bad trial. but i really do think we'll see more consolidation which we

the s&p 500 closed up 3/10 of a percent with the shares of comcast, merck and berger berkshire hathawayng with the latest results from herbalife. this is after the profits topped estimates. dwayne joins us on the phone from hope arkansas. give us the details of the reports that were better than what was estimated. dwayne:

. >>> coming up on al jazeera america, not everyone in merck can access the internet what the white houses doing to get more of the country online. ♪ >>> the white house is taking steps towards making it easier to get on internet. it's something most of us take for granted, but for some low income families the cost is too high. >>> public libraries used to be all about books, but it's access to the internet that draws people in in the digital age. this library provides free online browsing. and for parents keen to get their kids online it provides a vital service. >> this is a really nice library, so we enjoy coming and my son enjoys coming as well. >> reporter: it's that kind of service that the u.s. government wants to get into people's homes. it's a program that helps families pay their phone bills and also gets them online. the figures speak for themselves according to the latest u.s. census bureau findings 5 million households in the u.s. are without brood band and disproportionately they tend to be black or hispanic families. experts say if the u.s. is to remain competitive, everyon

they invest for the long-term like apple and merck earlier.est for what i called the battle for the corporate america. >> i couldn't agree more. i know we had to take on personal attacks by being independent and objective voices on this matter. as you respond on the finances. they had 5% falls and one-day falls ten times. it soared past that suggesting that this is a buying opportunity. this could be great to get on board. >> guys thank you very much. the good news is that we have an analyst on du pont right now. >> is the win good for the stock? they are currently 16 holds and one sell rating. joining us is mark conley and managing director who is overweight. you upgraded on april 27th and it sounded like it was primarily. now that lost the vote and doesn't have the nominees to the board. do you back off and are you concerned that it won't be the outperformer that you anticipated it would be? >> our upgrade was in anticipation that they would struggle. this out come is not surprising. . >> did you pond said it was fantastic and the cost cutti

whether it is the sec trying to regulate access to the internet, the epa merck -- regulating the air, this administration uses executive authority that many times, they do not have. and displace economic activity. americans are beginning to doubt whether our government and the basic institutions we have had to trust and have trusted for 239 years can be trusted anymore. we can fix this. we can fix this. you can do it with proper leadership, by creating sustained economic growth where more people have a chance at success. if we fix how we tax, regulate, embrace the energy revolution fix a broken immigration system fix our retirement system, this will be the most extraordinary time to be alive. i totally believe that and hope you do too. our children and greg -- grandchildren are deserving of that basic promise. [applause] mr. bush: if we will do that at home, we have to do it abroad. we see what happens when a president does not believe america's power in the world is a force for good. it starts by rebuilding our military. gilmore sequesters -- no more sequesters. we have to be vigilan

next week if you hear talk that j and j might buy that what is merck going to do? all these bigger pharmaceutical names, look at xbi, buy it on momentum through 230, that's how you trade the biotechs if you want to pick that up. >>> time for pops and drops. a pop of jcpenney up 6%. >> the numbers came out two days ago. i thought as a share hold, it was as good as you could expect. people want to point to they are not growing incrementally. i think they outperformed even in a weak environment. stay with the stock. >> down for 3d systems. >> pricing is an issue here. i think these stocks are over with for at least the foreseeable future. i'm a seller of triple d. >> drop for pandora. >> they lost a court decision but this is a name that has defied logic and myself over the last couple of months. even on this court decision, and down 3%, it still looks very constructive. i think you buy on the dip. >> in a pop for hertz. >> down 17% year to date. janay upped their partner's stake. that was helpful. they said they were going to raise prices for the summer. i think you

bristol-myers, merck,s astrozenica will be the big ones there. >> thank you. carter is looking at a similarity between biotech stocks and apple. explain. >> we know the health care sector is great. we know also that within the sector biotech is particularly good. let's take a look at the charts and try to figure this out together. so what i have is a few comparative charts just for fun. our thought here apple is going to brick out. so look at this correlation year-to-date, remarkably similar the king and the queen, let's call it that. king being apple. two best markets. it's not just year-to-date. here's over the past 12 months, virtually identical. here it is over two years. meaning relative strength is an important thing. it's not as though it's so ahead of itself which we'll see on the daily chart. here now is the same picture without, with the s&p. it's a blowout. so one could say it's ahead of itself. it really isn't if you look at the day-to-day. we'll get to that. long-term chart over the last several years. what my eye sees is this. a well defined chan

bristol-myers, roche, merck, astrazeneca, they will be there but the smaller guys puma and clovis theiggest movers. back to you. >> thank you, megan. carter is looking at a striking similarity between biotech stocks and apple. explain. >> well, these are the leaders. and we know that the sector is great, health care sector, and we know also that within the sector biotech is particularly good. let's look at some of the charts and we'll try to figure this out together. what i have is a few comparative charts just for fun because our thought here is apple is going to break out. look at this correlation year to date. i mean, remarkably similar. the king and the queen. let's call it that, the king being apple. two best areas of the market, well, it's not just year to date, here's over the past 12 months. virtually identical, well, here it is over two years, meaning relative strength is an important thing, money favors these assets and it's not as though it's so ahead of itself which we'll see on the daily chart. here now is the same picture without -- with the s&p. it's a blowout. one coul

that's a theme for the whole sector, but certainly for merck and pfizer.ly to split into several business units over the course of the next 18 months separating the innovative core from the established products and that could drive further value for shareholders. >> thank you as always for being with us. >> thanks for having me. all new season of the profit returns may 12th. this one also gives you the chance to help make the american dream come true. if you are on twitter, it's share the profit. for every retweet or share it gets, they are going to donate $1 to help small businesses across america. show support and share the profit. auto stales members for april have been coming in all day. how is that fort f150 selling? we will bring you the details and a huge sports weekend. maybe one of the biggest ever. how much money is going to be a bet on these various events from the nba play outs to the play weather paquiao flight. they are playing this song. stand by me in honor of benny king who died yesterday at the age of 76. we'll be right back. blap take a

over on-line piracy that next on kron >> pam moore: will have like there's gold owned by twitter and merckelivered a blow to pay-per-view by allowing thousands of people to watch them may weather pacheo fight for free people jeff stream it on their mobile device our tech reporter gabe slate explains this could have a huge impact umbrage future big live events. and is sparking a huge battle over all wind i received >> gabe slate: here is what happened dozens of people at a the $100 pay-per-view fee to watch the fight live through cable-tv fired up their scope back on their phone or tablets which led to stream live to the world whenever your camera is pointed that so they point their cameras at the tv once they did that they were still alive stream in the fight to anyone to watch for free 81 wed 3 free periscope or mayor mayor mayor of cat act installed on their device could save the $100 pay- per-view fee and watch it for free. the house and the people to combat the this and watch the fight his way dick costello see all twitter tweeting this out on for i ignite quell the winner is periscope

merck. and milin. >> instead of tongue-in-cheek, it was supposed to help, obamacare.d reduce your cost. it's not doing that. we are getting older population. so there will be more of that. there will also be the threat of the government doubling down and saying we'll regulate the price of medicine. we'll let you buy it from canada or some other place. >> i think this is -- the direct value of a pbm like express scripts. they're driving costs down. (?) that is their value. that's why they need to be there as an independent participant in health care costs. there's been issues where people have argued that they've made too much money. but they're the ones driving down the costs. look at what they did with gilead. they kept them off the formulary. they are a part o of solving the issues here. we're a big part of the company. if you want to play it, that's the one to be involved in. >> tune in to "making money" tomorrow night. charles, he won't be here. he and the crew they're out in las vegas. at the money show. they'll be live from that show. they'll have investment les

big competition going on between bristol myers and merck and astrazeneca and roche. they think bristol myers leads in lung cancer. he sees sales topping $16 boil lone in 2033. the smaller names often move more. thursday morning or wednesday after 5:00 p.m. we could be looking at clovis which has two drugs. one in lung cancer another in ovarian cancer. the drug in lung is competing with astrazeneca. investors looking for updates there. and puma biotech could move the stock. they are working on a drug for breast cancer. also because this drug is a potential take out target so that could boost its chances. >> are there any names that where this will be make-or-break where analysts are on the fence as to whether or not -- >> i haven't heard there's a completely binary event there. one we would highlight if there was. this is incremental but could still be for these smaller companies very stock moving. especially for puma. >> may 11th, for the science behind this is for real. the stock has gone from 65 down to 44 in about a two week period of time. if you're looking for r

. >> an airman from nearby creech air force base who was in the merck kyi abandons the car.the water rushes over the hood bennett notices a group of people gathered around a stranded prius. >> i don't know if they real that a large flow of muddy water is coming towards them. they have got to get out, man, they are going to get swept away. >> dixon and some other airmen are helping an elderly couple trapped in the prius. >> as i was looking around, that's when i saw the water rushing down the median towards us. and as soon as i saw that water, i told the guys that are helping them, all right, look, we have got to give this everything we have. >> watching the scene unfold, bennett is also worried that time is running out. >> i'm very concerned that they are going to have their backs turned and this wall of water is going to hit them. as i begin moving in that direction, the water swells up even further. and the grand marquis begins to float. >> get those people out. >> the force of the water pushes the 4,000-pound car wood the prius and the unsuspecting airmen? you just realiz

merck is $60. i think that's much cheaper thaj than glaxo because it has a better pipeline. say stay away. the rotation may still be playing out. domestic stocks have they been taken down enough? the answers you want on "mad money" tonight. over 40 million people are playing. now draft kings is making fantasy betting a reality. i will and costco netflix and amazon, three big names up for a bargain. but is there value in their shares or should you stay away. >>> plus a private supplier that could be the biggest threat to paypal. meet the ceo of karna. >>> and i say stake with cramer! strong can heal from miles away. unite us for a common good. and turn a simple video into endless laughter. strong can take you... all the way to the summit. oh my! so cool! think what strong can do for you. can i play too? at&t's network has the nation's strongest 4g lte signal. friday night, buddy. you are gonna need a wingman. and my cash back keeps the party going. but my airline miles take it worldwide. [ male announcer ] it shouldn't be this hard. with creditcards.com, it's easy to search h

. >> your list of partners, merck, a who's who of the pharma industry.ow worried do you get that one of them could start building the capability to do what you do. they have a lot of resources. >> i think it's quite interesting in the first two years of the company, coming from big pharma myself, i was very worried about a big pharma company putting 50 people, 100 people, and $100 million on the table to try to make m&a work. now where we are, i think we can do something quite unique. that only start-up in this country can do. which you know work together, fix problems, fix find solutions, and just make things happen quickly you know when we have a program at moderna, we don't set up a committee that three weeks from now is going to figure out how to do it we get people in the room, engineers, scientists, clinicians and we stay in the room until we fix it. >> you raised $1 billion recently. what's the theoretical valuation? >> the valuation has been reported when we did the fundraising in the just before christmas, was around $3 billion. >> what one i th

you can see the field behind merck the trees just snapped in half.up at a little bit higher elevation, down this road and around the bend a little bit. we hear that three homes are a total loss down there. we don't have access to those homes because the roads are cut off by trees and falling power lines. unfortunately, one person died in the storm yesterday. three others injured. one critical condition. and of course more storms today is a bad sign. we look out to our east and you can see, that's where most of the storms are forming. we do have -- we have gotten lucky so far. most of the storms have been to our south and to our east but you can see on the other side here cumulus clouds are building in the distance, a few storms possible as we go through the next couple of hours. one thing you do not want to hear when you have just been hit with an ef3 tornado, more storms but unfortunately, that's what we could be dealing with as we go through the afternoon hours. of course talking to the public information officer from this area and he said they hav

in the soft goods and health care segments merck j and j, pfizer -- they have been hurt by the strongollar. same with pop see co. their stocks begin to run, they lift off today. dear cater pillar, cummins, they could break out. lockheed martin, general dynamics, these companies are getting big international orders as other companies see the united states withdrawing from its role as the world's policeman as we heard earlier from the president in his press conference. the most logical place to go technology. apple, google and facebook. these three stocks have been stalled out. even as i could argue they all had amazing quarters. however, the currency head winds bluntded their sales dramatically. i think the estimates in the wake of these last quarters will be too low. i believe apple google and facebook could romp here. this was day one. along with sis coo co which shouldn't have been down after last night's terrific quarter. remember are rotations are vicious, we don't know when they will end. we dope know whether the dollar will stay weak and the euro continue to stay weak. neverthel

merck alexander polarsky key west florida. tevin lamar porterperry.ineer, kodiak, alaska. kevin francis deck watch officer, cutter harriett lane port smith, virginia. carlos manuel cutter tampa, port smith, virginia. andrew george ratie graduating with honors deck watch officer, cutter sherman honolulu hawaii. his commission will be presented by his father, u.s. coast guard, retired. jonathan alexander ray deck watch officer, st. petersburg florida. connor, christian regan deck watch officer. san juan puerto rico. stephen michael reynolds jr. student engineer cutter spencer, boston, massachusetts. his commission will be presented by his father, u.s. air force national guard. jessica lee richardson. deck watch officer cutter willow, new port rhode island. victor nicholas rosarta, student engineer, seattle, washington. nicholas walsh, rogers graduating with honors, deck watch officer cutter vigorous, virginia beach, virginia. devin francis rodi. deck watch officer, cutter dependable, virginia beach, virginia. her commission will be presented by her sist

should we be concerned that all is not what one would have hoped over at merck?have overdelivered against the estimates in terms of top line. we are growing sales by 15%. all of our business sectors are growing organically. of course we also have some tail wind from positive developments as well as from acquisitions. electronic materials is included for another full quarter as inquisitive growth. we slightly missed the -- the reasons here indeed somewhat higher are -- which we have announced as we are ramping up our strategic collaboration with pfizer. we have some competitive pressure on our biggest franchise and facing some less royalty pames, income. we have -- our quantitative guiding for 2015. we have a quite challenging year in 2015 and delivered a solid guidance. manus: are we going to see more deals with pfizer? >> excuse me? manus: should we expect to see more deals similarly to the one you did with pfizer? you're number four. you're up 30% this year. >> of course, the deal with pfizer is somewhat special because it is pretty far-reaching. our first prio

the president of merck investments on the dollar stronger.erns and tom keene with the government. tom: "bloomberg surveillance." futures up seven. axel merk a genius. we will get to that in a moment. here is olivia sterns. olivia: navy ships are escorting u.s. commercial ships through the strait of hormuz at the mouth of the persian gulf. officials say it is to make sure that they face no interference from iranian ships. it is being adopted to in response to what washington views as provocative behavior. a compromise gop budget promises to speed up the repeal of the health care law and would give the pentagon and next to $30 billion next year. it promises to balance the budget in nine years with more than $5 trillion in spending cuts. the nonbinding plan heads to the senate next week. president obama's choosing his adopted hometown for his presidential library get it will be built on the south side of chicago. the university of chicago has identified two possible sites near the obama family home. an official announcement is expected within a

betty: on top of all this, is there $2 trillion of retail money that has yet to be put to merck -- putrket? none of this is going to encourage any of that money to come in. bob: yes, but it doesn't seem to slow the inflow. you would think that the ordinary mom and pop retail investor the game is fixed. apparently, it's just business as usual. olivia: mom-and-pop investors have been putting aside money. they have missed out on the enormous equity rally. betty: it has not stopped the rally. bob: they will come in just as the price starts going down. betty: exactly. stocks are getting ready to start trading. let's bring in mohamed el-erian and former ceo of pimco. great to see you on this friday. having judged what you saw in the economic numbers and what the fed said in their statement where do you think we will be with interest rates? mohamed: the fed is keeping all their cards until june. the path will be extremely shallow. third, the destination will be lower than we have seen in the past. we are looking at the loosest tightening cycle in the history in the modern history of the feder

merck, ibm a lot of tech names leading the way.on the other hand during these hours around is weighing on the s&p 500. a multiyear low they are. 23% the slowest sales growth imports in growth imports and quarters with a tough outlook. down 6.5% coach down 5%. a $775 million deal antibiotic free and hormone free 4%. ned your car for four years. you named it brad. you loved brad. and then you totaled him. you two had been through everything together. two boyfriends. three jobs. you're like "nothing can replace brad!" then liberty mutual calls. and you break into your happy dance. if you sign up for better car replacement, we'll pay for a car that's a model year newer with 15,000 fewer miles than your old one. see car insurance in a whole new light. liberty mutual insurance. stuart: this special fox business report allegations the faa is bending the rules to get a more diverse workforce. all of this when the faa needs to hire 1000 new air traffic controllers per year for the next 10 years and to pay not too shabby. adam shapiro has de

it's also cited drugs from merck and bristol-myers. they could be 1 and any company working in cancer drugs could be affected by this. >> a good developing story. a news alert, five-year notes are up for action. tracking the action at the cme. yesterday's two-year note auction. you gave it a c plus. what's the great today? >> a b minus and we moved up about a half grade. b minus is the way it sits. 35 billion. five-year notes. that was the issue market in terms of pricing on how far back they had to go in this action. # that's a little light from 2.58 average. 58.5 and we give it a b minus and tomorrow will be seven years, 29 billion and the longer maturity will be the better of the strategy of investors and auction giving us clues on the day to day trade. >> bring up the board and see what's going on the benchmark. late yesterday, today we are sitting at it and we have got that today. we can show you. anyway, here it comes. the 10-year at 2.15. checking what's happening on the stock market. the dow and the s&p are moving higher. rebou

. >> candidate for the united states of merck.ton claims she has quote, true solutions to this country's immigration system as she goes head-to-head with the republican party. and west meets east this week as some of the most followed voices in silicon valley descend upon new york city live talking innovation, and a big money behind it. mike huckabee is sixth hopeful vying for the gop vote. john roberts is on the ground in arkansas. john. >> govern to you it is quiet here now at university of arkansas at hope feels like the morning after fat tuesday in new orleans because it was a huge celebration here.

merck down 1.8% after disappointing first quarter results. this due to costs associated with the planned acquisition of sigma aldridge. let's get to annetta with more details on the story. >> the numbers are disappointing and it's the only share here on the german market side which can't benefit from all the ecb or greece optimism. let me run you through the numbers. net profit down 13%. the company is because of financing cost of its biggest acquisition ever in the company's history. they're essentially supplying technology and instruments for laboratories for 17 billion u.s. dollars. the financing cost caused a weighing on the results in the first quarter but looking at the divisions also there, health care unit is not doing well. they have drugs, like the drug against ms and those blockbuster drugs have suffered a severe blow in the first quarter. sales are down 16% where as sales for the cancer drug is down by 6%. also is they need to invest more money into research for new drugs and new other drugs in general because of course they need

they are here to stay and bristol and merck and astrazeneca are the main players.e of the weekend is who will combine best with the major pd 1 players. of all the stocks that we're following, insight is going to be my top nominee to make it there in combination with the pd one. they have a drug called an ida one inhibitor. we will get additional data on that molecule towards the early part of the year. it looks like it will be a combinable agent with the pd ones. >> thank you very much. eric schmitt, thank you. thanks for stopping by. tonight forget to watch mad money at 6:00 eastern time. melissa? >> back to the other big story at this hour the huge move in oil is up about 5% now. let's bring in the chief commodity strategist. good to see you. thank you for having me. >> for doesn't look like the normal culprits. it's not commensurate with the oil move and the inventory was mixed. production was higher even though inventories dropped. >> it's a rate count number. the 13 drops this week. there was an expectation that it might be a lower number. last week we had one

winners, merck, jpmorgan, leading the way on the dow green mountain coffee roasters coming under heavyd under pressure so keep an eye on that one. intraday let's take a look at las vegas sands right now. las vegas sands making a move to the upside. traders brought this one to my attention, some heavy volume. so keep an eye on that and the casinos overall have been in the news particularly because of mgm resorts, first quarter revenue fell 11%. so we've seen mgm coming under some pressure. big picture, oil pulling back, gold gaining. more "varney & company" coming up. stuart: can hillary clinton be trusted? trusted enough to be president? "the washington post" raised the question. just look at this headline from "the washington post" that apoored over the weekend. quote: for hillary clinton a trust deficit to surmount. joining us now is daniel harper author of the book "clinton inc.." dan yell, that headline went on to say there are doubts about whether she is honest enough to be president. coming from "the washington post," i think that's pretty strong stuff. >> yeah, absolutely. but i

a similar pattern followed for merck. you might wonder why this happened. in one word gilead. approved and brought in more than $10 billion last year. j & j's olysio was approved and combined with sovaldi. but then at the end of last year gilead's own combination pill harvoni was approved. in two months it brought in $2 billion in revenue. that may lead to the erosion analysts are modeling for olysio. they do cure this disease. new generations of drugs have been coming on the market so fast. j & j reiterated its commitment to the hepatitis c space announcing a deal with gilead. >> back to you guys. >> good stuff. it's good for patients if nothing else. >> absolutely. >>> heading to the close, 20 minutes to go in the trading session here. early on we talked about record highs for the dow and the s&p. doesn't look like that's going to happen at least for the moment. the industrial average is now down 26 points with the s&p down more than a point and a half. >>> up next on the heels of today's fed minutes, the rate hike debate rages on. what should fed chair janet yellen do and w

does open up also, some say, for possible gains from their competition from the likes of perhaps a merck or roche in switzerland to gain ground on particular drugs being put out by bristol-myers squibb. the bottom line the results for positive for this cancer-fighting drug but not as positive as some investors would have hoped for. it does perhaps, leave the door open for competition of the likes of other drug companies. so, again, that's the reason why. those stocks shares are down by about 8% right now towards their worst levels today. we'll keep an eye on bristol-myers as we head towards the closing bell. >> meg tirrell will be at that asco conference on monday. apparently a lot of fireworks to come out of that as well. >> these conferences move the shares around. glad she'll be down there covering it for us. >> now to the humana story. shares surging 17% last i checked on talk that it is reportedly exploring a sale after being approached by some of its rivals. >> "mad money's" jim cramer was talking about this exact scenario last week. >> we also have an important analyst meeting wed

the big four are bristol myers, merck and astrazeneca. the market with their drugs and people will be looking to see how they work on their own in different kinds of cancer and how they work in combination with other kinds of drugs. a big focus on amino therapy. but, of course the companies that move are smaller companies. cloves will have some data on a lung cancer drug where werit's competing very closely with astrazeneca. that could be a hot one to watch. also in medivation they have a big prostate cancer drug. they are testing it in other kinds of cancers. interesting to see what that does. puma was an interesting one. the data sets came out a few weeks ago. their breast cancer drug seemed to disappoint investors. some analysts think that data may have been misinterpreted. how they communicate with their have esters at the conference. on monday three big stocks to watch. another one is just pfizer. they launched this big breast cancer drug and interesting to see how that comes out. a lot of these executives on with us on monday starti

that's bristol myers and merck.re big companies and we should be getting a better understanding of how the drugs work in combination and by themselves in different cancers. a lot of data coming out in nonsmall cell lung cancer last night so people excited about that but the big mover is puma biotech. their breast cancer drug disappointed some investors and analysts so with the magnitude of benefit it showed so really falling there and part of the reason it's sinking is this company is not to be a takeover target potentially and this dampens it's prospects there. analysts saying they look better than you think. wait until the meeting. we'll hear more about it but this did disappoint people and maybe this means there's a narrower potential indication for this drug. maybe it won't do as much as people are expecting. we'll see how it does in terms of the takeover prospects for puma. >> i'm wondering how big it is. >> it's about a 6 or $7 billion market cap. >> was. >> was yesterday. >> was yesterday. >> 20% hair cut. th

. >> and you know this is merck. >> i do.that will have to get resolved but my guess is this won't happen as it's reported this morning. but drug companies will be more careful in terms of how they set initial prices. >> and when you're -- the big complaint is that obamacare didn't allow medicare to negotiate prices as a huge -- so the pharmacy benefit -- in a free market the pbms at leasting agate a lot of cash and can put some pressure on the drug companies if it needs to be. >> what worries me about reading something like this is it's the patients who are stuck in the middle while this debate rages on who can't get the care that they need. >> you're right. >> and that's the concern. >>> let's talk a little bit more about the stock market today. u.s. stocks are set to bounce back this morning. we are joined right now on set by larry cantor the head of research at barclay's. thanks for being here this morning. >> pleasure. >> what do you think about where things stand right now? the steady march of the market but not necessa